Estradiol valerate and estradiol valerate/dienogest (Natazia) tablets: The first four-phasic oral contraceptive

P and T

Volumn 35, Issue 11, 2010, Pages 614-617

  Ndefo, Uche Anadu ^a   Mosely, Nina ^b  

^a TEXAS SOUTHERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CESIA; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST PLUS ESTRADIOL VALERATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; GRISEOFULVIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; KETOCONAZOLE; LAMOTRIGINE; MESTRANOL PLUS NORETHISTERONE; NATAZIA; NECON 1/50; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENYTOIN; RIFAMPICIN; TOPIRAMATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACNE; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG WITHDRAWAL; EYE IRRITATION; FURUNCULOSIS; HEADACHE; HUMAN; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; MENTAL INSTABILITY; METRORRHAGIA; SHORT SURVEY; SIDE EFFECT; TABLET; WEIGHT GAIN;

EID: 78649490211     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (11)

1. Mosher WD, Jones J. Use of contraception in the United States: 1982-2008. Vital Health Statistics, 2010, Series 23, No. 29. Available at: www.cdc.gov/nchs/ data/series/sr-23/sr23-029.pdf. Accessed July 26, 2010.
2. Centers for Disease Control (CDC). U.S. medical eligibility criteria for contraceptive use, 2010. Morb Mortal Wkly Rep, May 2010. Available at: www.cdc.gov/mmwr/pdf/rr/rr59e0528.pdf. Accessed August 10, 2010.
3. Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: Results of two prospective, randomized, open-label studies. Contraception 2008;78(3):218-225.
4. FDA approves new combination prod uct oral contraceptive. FDA, May 6, 2010. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm211176.htm. Accessed July 26, 2010.
5. Natazia (estradiol valerate and estradiol valerate/dienogest), package insert. Berk eley, Calif.; Bayer Healthcare Pharmaceuticals, Inc.; May 2010.
6. Zeun S, Lu M, Uddin A, et al. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contracept Reprod Health Care 2009;14(3):221-232.
7. Palacios S, Wildt L, Parke S, et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): A phase III trial. Eur J Obstet Gynaecol Reprod Biol 2010:149(1):57-62.
8. Ahrendt HJ, Makalova D, Parke S, et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: Seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. Contraception 80;2009:436-444.
9. Frye CA. An overview of oral contraceptives: Mechanism of action and clinical use. Neurology 2006:S29-S36.
10. Natazia, product monograph, Lexi- Comp. Available at: www.crlonline.com. Accessed August 9, 2010.
11. Morris & Dickson. Web Portal for Harris County Hospital District. Available at: www.mdwebportal.net/mdwp/Default.aspx. Accessed July 26, 2010.